0000000000118453

AUTHOR

Lin T

showing 2 related works from this author

First Measurement of the Absolute Branching Fraction of Λ→pμ−ν¯μ

2021

The absolute branching fraction of Λ→pμ−ν¯μ is reported for the first time based on an e+e− annihilation sample of 10×109 J/ψ events collected with the BESIII detector at s=3.097 GeV. The branching fraction is determined to be B(Λ→pμ−ν¯μ)=[1.48±0.21(stat)±0.08(syst)]×10−4, which is improved by about 30% in precision over the previous indirect measurements. Combining this result with the world average of B(Λ→pe−ν¯e), we obtain the ratio {[Γ(Λ→pμ−ν¯μ)]/[Γ(Λ→pe−ν¯e)]} to be 0.178±0.028, which agrees with the standard model prediction assuming lepton flavor universality. The asymmetry of the branching fractions of Λ→pμ−ν¯μ and Λ¯→p¯μ+νμ is also determined, and no evidence for CP violation is fo…

PhysicsMeasurementAnnihilationBranching010308 nuclear & particles physicsBranching fractionmedia_common.quotation_subjectGeneral Physics and AstronomyAbsoluteTime based01 natural sciencesAsymmetryNOStandard ModelSubatomär fysikSubatomic Physics0103 physical sciencesCP violationAtomic physics010306 general physicsLeptonmedia_commonPhysical Review Letters
researchProduct

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

2017

Background: Experimental and clinical data suggest that reducing inflammation without affecting lipid levels may reduce the risk of cardiovascular disease. Yet, the inflammatory hypothesis of atherothrombosis has remained unproved. Methods: We conducted a randomized, double-blind trial of canakinumab, a therapeutic monoclonal antibody targeting interleukin-1β, involving 10,061 patients with previous myocardial infarction and a high-sensitivity C-reactive protein level of 2 mg or more per liter. The trial compared three doses of canakinumab (50 mg, 150 mg, and 300 mg, administered subcutaneously every 3 months) with placebo. The primary efficacy end point was nonfatal myocardial infarction, …

0301 basic medicine030204 cardiovascular system & hematologylaw.invention0302 clinical medicinec-reactive proteinRandomized controlled triallawCardiovascular Diseasemiddle ageddouble-blind methodantibodiesMyocardial infarctionhumansStrokeinterleukin-1betabiologyAntibodies MonoclonaldrugGeneral MedicineLipidAged; anti-inflammatory agents; antibodies; monoclonal; antibodies; monoclonal; humanized; atherosclerosis; c-reactive protein; cardiovascular diseases; dose-response relationship; drug; double-blind method; female; humans; incidence; infections; interleukin-1beta; lipids; male; middle aged; myocardial infarction; neutropenia; secondary prevention; strokestrokeAnti-Inflammatory AgentagedEditorialfemalemyocardial infarctionAtherosclerosiMonoclonalsecondary preventionHumanmedicine.drugmedicine.medical_specialtymonoclonalNeutropeniaAntibodies Monoclonal HumanizedInfectionsPlaceboaged; anti-inflammatory agents; antibodies monoclonal; atherosclerosis; c-reactive protein; cardiovascular diseases; dose-response relationship drug; double-blind method; female; humans; incidence; infection; interleukin-1beta; lipids; male; middle aged; myocardial infarction; neutropenia; secondary prevention; stroke; medicine (all)anti-inflammatory agentsdose-response relationshiplipids03 medical and health sciencesmaleInternal medicinemedicineneutropeniamedicine (all)Dose-Response Relationship Drugbusiness.industryAntiinflammatory Therapy Canakinumab for Atherosclerotic DiseaseC-reactive proteinmedicine.diseaseinfectioncardiovascular diseasesSurgeryCanakinumab030104 developmental biologyincidencebiology.proteinatherosclerosisbusinessNew England journal of medicine
researchProduct